Focus Rheums| ACR Convergence 2024 Previews

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Report on EU’s Experience with Biosimilar Drugs Released: Will U.S. Experience Be Similar?

  |  Issue: October 2017  |  

“The ACR’s white paper on biosimilars will inform prescribers about the FDA approval process, scientific and clinical issues, such as extrapolation, immunogenicity, switching and interchangeability; and issues related to cost, access and the mechanics of prescribing,” Dr. Worthing says. “The purpose of the white paper is to inform our members about biosimilars, reassure them about the scientific rigor used by regulatory authorities and boost confidence in prescribing biosimilars.”

As of publication, this paper was still in draft form.

ADVERTISEMENT
SCROLL TO CONTINUE

Vanessa Caceres is a medical writer in Bradenton, Fla.

Reference

  1. European Medicine Agencies and European Commission. Biosimilars in the EU: Information guide for healthcare professionals. 2017.

Related Articles
    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

    Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing

    The use of biosimilars for rheuma­tology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to Seoyoung…